Oesophageal Chemoradiotherapy in the UK-Current Practice and Future Directions

Clinical Oncology

Volumn 25, Issue 6, 2013, Pages 368-377

  Gwynne, S ^a,b   Falk, S ^c   Gollins, S ^b,d   Wills, L ^b   Bateman, A ^e   Cummins, S ^f   Grabsch, H ^g   Hawkins, M A ^h   Maggs, R ^b   Mukherjee, S ^h   Radhakrishna, G ⁱ   Roy, R ^j   Sharma, R A ^h   Spezi, E ^b   Crosby, T ^b  

^a SINGLETON HOSPITAL   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d GLAN CLWYD HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ St James's Institute of Oncology   (United Kingdom)

^j CASTLE HILL HOSPITAL   (United Kingdom)

more..

Author keywords

Chemoradiotherapy; Oesophageal

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; VINBLASTINE;

ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; DOSE RESPONSE; DOSIMETRY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; RADIATION DOSE; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; UNITED KINGDOM;

CHEMORADIOTHERAPY; CLINICAL TRIALS, PHASE II AS TOPIC; ESOPHAGEAL NEOPLASMS; GREAT BRITAIN; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84877121946     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.01.006     Document Type: Article

References (62)

1. Gwynne S., Hurt C., Evans M., et al. Definitive chemoradiation for oesophageal cancer - a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol 2011, 23:182-188.
2. Hingorani M., et al. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer - do we need another randomised trial?. Clin Oncol 2011, 23(10):696-705.
3. Hurt C.N., et al. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 2011, 11:466.
4. Button M.R., Staffurth J., Crosby T.D.L. National variations in the treatment of oesophageal cancer with chemoradiotherapy. Clin Oncol 2007, 73(3):S25.
5. Wills L., et al. The effect of planning algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial. Radiother Oncol 2009, 93:462-467.
6. Gwynne S., et al. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: a United Kingdom definitive chemoradiotherapy trial for esophageal cancer. Int J Radiat Oncol Biol Phys 2011, 81:S67-S68.
7. Geh I.J., et al. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006, 78:236-244.
8. Minsky B.D., et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
9. Herskovic A., Martz K., al Saraff M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593-1598.
10. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005, 23:2310-2317.
11. Bedenne L., Michel P., Bouche O., et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007, 25:1160-1168.
12. vanHagen P., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New Engl J Med 2012, 366:2074-2084.
13. Pöttgen C., Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer - a meta-analysis of the randomized trials. Cancer Treat Rev 2012, 38:599-604.
14. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 2006, 335:462-467.
15. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone insquamous-cell cancer of the oesophagus. N Engl J Med 1997, 337:161-167.
16. Urba S.G., Orringer M., Turrisi A., et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19(2):305-313.
17. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomized controlled phase III trial. Lancet Oncol 2005, 6:659-668.
18. Tepper J., Krasner M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
19. SAKK 75/08. [accessed 04.03.13]. http://www.agmt.at/files/oegho/SAKK_7508_OEGHO_Mai11.pdf.
20. Matzinger O., et al. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009, 92:164-175.
21. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002, 359:1727-1733. Group MRCOCW.
22. Rice P.F., Crosby T.L.D., Roberts S.A. Variability of the carina-incisor distance as assessed by endoscopic ultrasound. Clin Oncol 2003, 15:383-385.
23. Thomas E., et al. The role of endoscopic ultrasound (EUS) in planning radiotherapy target volumes for oesophageal cancer. Radiother Oncol 2004, 73:149-151.
24. Macmanus M., et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009, 91:85-94.
25. Hill E.J., et al. Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research?. Crit Rev Oncol Haematol 2012, 83(3):353-387.
26. Gillham C.M., Reynolds J., Hollywood D. Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation. World J Surg Oncol 2007, 5:97.
27. vanHeijl M., et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008, 8:21.
28. Dieleman E.M.T., et al. Four dimensional computed tomographic analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys 2007, 67(3):775-780.
29. Yaremko B.P., et al. Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 2008, 70:145-153.
30. Yamashita H., et al. Four-dimensional measurement of the displacement of internal fiducial markers during 320-multislice computed tomography scanning of thoracic esophageal cancer. Int J Radiat Oncol Biol Phys 2011, 79:588-595.
31. Zhao K.L., et al. Evaluation of respiratory-induced target motion for esophageal tumours at the gastroesophageal junction. Radiother Oncol 2007, 84:283-289.
32. Yang G.Y., McClosky S.A., Khushalani N.I. Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers. Gastrointest Cancer Res 2009, 3(Suppl. 1):S6-10.
33. Mukherjee S., et al. The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. Clin Oncol 2003, 15:115-120.
34. Hawkins M.A., et al. Volumetric modulated arc therapy planning for distal oesophageal malignancies. Br J Radiol 2012, 85:44-52.
35. Pearson M., et al. Implementation of an advanced treatment planning algorithm in the treatment of lung cancer with conventional radiotherapy. Clin Oncol 2009, 21:168-174.
36. Irvine C., et al. The clinical implications of the collapsed cone planning algorithm. Clin Oncol 2004, 16:148-154.
37. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010, 22:643-657.
38. Nutting C.M., et al. A comparison of conformal and intensity modulated techniques for oesophageal radiotherapy. Radiother Oncol 2001, 61:157-163.
39. Fu W.H., Wang L.H., Zjou M.Z. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper oesophageal carcinoma. World J Gastroenterol 2004, 10:1098-1102.
40. Roy R., et al. Intensity modulated radiotherapy for radical treatment of oesophageal and junctional tumours - a dosimetric study. Ann Oncol 2012, 23:S4.
41. Chandra A., et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal oesophageal cancer. Radiother Oncol 2005, 77:247-253.
42. Wang S.L., et al. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol 2006, 12:5501-5508.
43. Hsu F.M., et al. Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy. Ann Surg Oncol 2009, 16:1669-1677.
44. Chen Y.J., et al. Image-guided radiotherapy of esophageal cancer by helical tomotherapy; acute toxicity and preliminary clinical outcome. J Thoracic Dis 2009, 1:17-22.
45. Chen Y.J., et al. Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim 2007, 32:166-171.
46. Fenkell L., et al. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical oesophagus. Radiother Oncol 2009, 89:287-291.
47. Oldham M., et al. Cone-beam CT-guided radiation therapy: a model for on-line application. Radiother Oncol 2005, 75:271-278.
48. Hawkins M.A., et al. Cone beam CT verification for oesophageal cancer - impact of volume selected for image registration. Acta Oncol 2011, 50:1183-1190.
49. Hawkins M.A., et al. Cone beam computed tomo-graphy-derived adaptive radiotherapy for radical treatment of oesophageal cancer. Int J Radiat Oncol Biol Phys 2010, 77(2):378-383.
50. Bissonnette J.P., et al. Quantifying interfraction and intrafraction tumour motion in lung stereotactic body radiotherapy using respiration-correlated cone beam computed tomography. Int J Radiat Oncol Biol Phys 2009, 75:688-695.
51. Courrech Staal E.F., et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010, 97(10):1482-1496.
52. Javle M.M., et al. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest 2009, 27:193-200.
53. Allum W.H., et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-5067.
54. Cunningham D., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl J Med 2008, 358:36-46.
55. Aklilu M., Ilson D.H. Targeted agents and oesophageal cancer - the next step?. Semin Radiat Oncol 2006, 17:62-69.
56. Mulligan E.D., et al. Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. Eur J Surg Oncol 2004, 30:313-317.
57. Khan O.A., Cruttenden-Wood D., Toh S.K. Is an involved circumferential resection margin following oesphagectomy for cancer an important prognostic indicator?. Interactive Cardiovasc Thoracic Surg 2010, 11(5):645-648.
58. Chao Y.K., et al. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 2011, 18(2):529-534.
59. Harvin J.A., et al. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thoracic Cardiovasc Surg 2012, 143(2):412-420.
60. Salih T., et al. Prognostic significance of cancer within 1 mm of the circumferential resection margin in oesophageal cancer patients following neo-adjuvant chemotherapy. Eur J Cardio-Thoracic Surg 2012, 43:562-567.
61. Scheer R.V., Fakiris A.J., Johnstone P.A. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys 2011, 80(4):996-1001.
62. Bollschweiler E., et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 2011, 92(6):2020-2027.